论文部分内容阅读
摘要目的研究DWI评估的转移性去势抵抗性前列腺癌(mCRPC)骨转移量与mCRPC已知预后因素及总体生存率(OS)的相关性。材料与方法本回顾性研究获得伦理委员会批准,所有病人签署知情同意书。分析了2010年6月—2013年2月间53例转移性去势抵抗性前列腺癌病人开始新一轮抗癌治疗时的全身DWI。共43例合格病人在全身DWI上证
Abstract Objective To investigate the correlation between DWI-assessed bone metastases in mCRPC and the known prognostic factors and overall survival (OS) of mCRPC. Materials and Methods The retrospective study was approved by Ethics Committee and all patients signed informed consent. 53 cases of metastatic castration-resistant prostate cancer patients from June 2010 to February 2013 were analyzed for systemic DWI when they started a new round of anticancer treatment. A total of 43 cases of qualified patients in the whole body DWI card